Calliditas Therapeutics AB

18.95+0.8827+4.89%Vol 3.27K1Y Perf -36.83%
Jun 24th, 2022 15:59 DELAYED
BID9.53 ASK19.10
Open18.86 Previous Close18.07
Pre-Market- After-Market-
 - -  - -%
Target Price
57.00 
Analyst Rating
Strong Buy 1.00
Potential %
200.79 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.50
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
31.01 
Earnings Rating
Market Cap503.80M 
Earnings Date
18th Aug 2022
Alpha-0.02 Standard Deviation0.19
Beta2.02 

Today's Price Range

18.4919.00

52W Range

12.5533.19

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
6.34%
1 Month
2.27%
3 Months
-0.26%
6 Months
-28.00%
1 Year
-36.83%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CALT18.950.88274.89
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.47-0.85-80.85
Q04 2021-0.79-0.95-20.25
Q03 2021-0.840.05105.95
Q02 2021-0.72-0.76-5.56
Q01 2021-0.69-0.6013.04
Q04 2020-0.65-0.79-21.54
Q03 2020-0.39-0.62-58.97
Q02 2020-0.40-0.3122.50
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date18th Aug 2022
Estimated EPS Next Report-0.74
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume3.27K
Shares Outstanding26.59K
Shares Float26.59M
Trades Count57
Dollar Volume61.41K
Avg. Volume6.08K
Avg. Weekly Volume3.93K
Avg. Monthly Volume6.13K
Avg. Quarterly Volume8.16K

Calliditas Therapeutics AB (NASDAQ: CALT) stock closed at 18.95 per share at the end of the most recent trading day (a 4.89% change compared to the prior day closing price) with a volume of 3.27K shares and market capitalization of 503.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 34 people. Calliditas Therapeutics AB CEO is Renée Aguiar-Lucander.

The one-year performance of Calliditas Therapeutics AB stock is -36.83%, while year-to-date (YTD) performance is -23.47%. CALT stock has a five-year performance of %. Its 52-week range is between 12.5501 and 33.19, which gives CALT stock a 52-week price range ratio of 31.01%

Calliditas Therapeutics AB currently has a PE ratio of -7.40, a price-to-book (PB) ratio of 5.53, a price-to-sale (PS) ratio of 15.46, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.66%, a ROC of -48.13% and a ROE of -56.27%. The company’s profit margin is -%, its EBITDA margin is -202.00%, and its revenue ttm is $30.64 Million , which makes it $1.15 revenue per share.

Of the last four earnings reports from Calliditas Therapeutics AB, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.74 for the next earnings report. Calliditas Therapeutics AB’s next earnings report date is 18th Aug 2022.

The consensus rating of Wall Street analysts for Calliditas Therapeutics AB is Strong Buy (1), with a target price of $57, which is +200.79% compared to the current price. The earnings rating for Calliditas Therapeutics AB stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Calliditas Therapeutics AB has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Calliditas Therapeutics AB has a Buy technical analysis rating based on Technical Indicators (ADX : 8.50, ATR14 : 1.08, CCI20 : 44.28, Chaikin Money Flow : 0.13, MACD : 0.27, Money Flow Index : 48.98, ROC : -2.57, RSI : 56.26, STOCH (14,3) : 66.60, STOCH RSI : 1.00, UO : 54.05, Williams %R : -33.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Calliditas Therapeutics AB in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Calliditas Therapeutics AB

Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.

CEO: Renée Aguiar-Lucander

Telephone: +46 84113005

Address: Kungsbron 1, C8, Stockholm SE-111 22, , SE

Number of employees: 34

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

58%42%

News

Stocktwits